Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations

Plasmablastic lymphoma is a relatively new entity that is considered to be a diffuse large B-cell lymphoma with an unique immunophenotype and a predilection for the oral cavity. We present a 50 year-old HIV-positive, bisexual, white male with a CD4 count 300/mm 3 and a viral HIV-RNA polymerase chain...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oral oncology 2002, Vol.38 (1), p.96-102
Hauptverfasser: Flaitz, C.M., Nichols, C.M., Walling, D.M., Hicks, M.J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 102
container_issue 1
container_start_page 96
container_title Oral oncology
container_volume 38
creator Flaitz, C.M.
Nichols, C.M.
Walling, D.M.
Hicks, M.J.
description Plasmablastic lymphoma is a relatively new entity that is considered to be a diffuse large B-cell lymphoma with an unique immunophenotype and a predilection for the oral cavity. We present a 50 year-old HIV-positive, bisexual, white male with a CD4 count 300/mm 3 and a viral HIV-RNA polymerase chain reaction (PCR) load of 237 copies/ml, who developed a painful, purple-red mass in the edentulous area of the maxillary right first molar. Erythematous gingival enlargements of the interdental papillae were seen in three of the dental quadrants. In addition, the patient was being managed with antiretroviral therapy and liposomal doxorubicin for recurrent cutaneous Kaposi's sarcoma (KS). Although oral KS was suspected, the gingival lesions were biopsied because they were refractory to chemotherapy and a lymphoma could not be excluded. Histopathologic examination revealed a lymphoid malignant neoplasm, consistent with a plasmablastic lymphoma. Immunoreactivity with vs38c, CD79a, kappa light chain, and IgG was readily identified in tumor cells; while only focal cells expressed CD20 and LCA (CD45RB). CD56, CD3, lambda light chain, and EMA were non-reactive. EBV was detected in the tumor by Southern hybridization, PCR amplification, in situ hybridization for EBER-1 DNA, and immunohistochemistry for latent membrane protein-1. The same tumor was negative for HHV-8 by PCR. Recognition of plasmablastic lymphoma is important, because it represents an HIV-associated malignancy that predominately involves the oral cavity, may mimic KS and has a poor prognosis.
doi_str_mv 10.1016/S1368-8375(01)00018-5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71346456</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1368837501000185</els_id><sourcerecordid>71346456</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-bd325d5b496e1f66430b9e689337f930493b3a3e0202ae2bfcc8b316e7fa13bc3</originalsourceid><addsrcrecordid>eNqFkMtu1TAQQC0Eog_4BFA2oLIIeOzYidkgVEFbqVJBPLbW2JmoRnlcbF_Q_fu6vam67GZmFmdeh7FXwN8DB_3hB0jd1Z1s1QmHd5xz6Gr1hB1C15qaKyOflvoeOWBHKf0pkALFn7MDgFapTrSH7Pu3EdOErsQcfDXups31MuHHCufq_OJ3jSktPmCmvqI5h7yr_od8XW1imDDuqiXiWE04h4FSxhyWOb1gzwYcE71c8zH79fXLz9Pz-vLq7OL082XtGyFy7XopVK9cYzTBoHUjuTOkOyNlOxjJGyOdRElccIEk3OB95yRoagcE6bw8Zm_3czdx-bst6-0UkqdxxJmWbbItyEY3Sj8KQidMY4wpoNqDPi4pRRrs-qYFbm-l2zvp9tao5WDvpFtV-l6vC7Zuov6ha7VcgDcrgMnjOEScfUgPnGxAGMEL92nPUfH2L1C0yQeaPfUhks-2X8Ijp9wAokKeSA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18294999</pqid></control><display><type>article</type><title>Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Flaitz, C.M. ; Nichols, C.M. ; Walling, D.M. ; Hicks, M.J.</creator><creatorcontrib>Flaitz, C.M. ; Nichols, C.M. ; Walling, D.M. ; Hicks, M.J.</creatorcontrib><description>Plasmablastic lymphoma is a relatively new entity that is considered to be a diffuse large B-cell lymphoma with an unique immunophenotype and a predilection for the oral cavity. We present a 50 year-old HIV-positive, bisexual, white male with a CD4 count 300/mm 3 and a viral HIV-RNA polymerase chain reaction (PCR) load of 237 copies/ml, who developed a painful, purple-red mass in the edentulous area of the maxillary right first molar. Erythematous gingival enlargements of the interdental papillae were seen in three of the dental quadrants. In addition, the patient was being managed with antiretroviral therapy and liposomal doxorubicin for recurrent cutaneous Kaposi's sarcoma (KS). Although oral KS was suspected, the gingival lesions were biopsied because they were refractory to chemotherapy and a lymphoma could not be excluded. Histopathologic examination revealed a lymphoid malignant neoplasm, consistent with a plasmablastic lymphoma. Immunoreactivity with vs38c, CD79a, kappa light chain, and IgG was readily identified in tumor cells; while only focal cells expressed CD20 and LCA (CD45RB). CD56, CD3, lambda light chain, and EMA were non-reactive. EBV was detected in the tumor by Southern hybridization, PCR amplification, in situ hybridization for EBER-1 DNA, and immunohistochemistry for latent membrane protein-1. The same tumor was negative for HHV-8 by PCR. Recognition of plasmablastic lymphoma is important, because it represents an HIV-associated malignancy that predominately involves the oral cavity, may mimic KS and has a poor prognosis.</description><identifier>ISSN: 1368-8375</identifier><identifier>EISSN: 1879-0593</identifier><identifier>DOI: 10.1016/S1368-8375(01)00018-5</identifier><identifier>PMID: 11755827</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>AIDS ; Antiretroviral Therapy, Highly Active - methods ; Biological and medical sciences ; CD38 ; Diagnosis, Differential ; EBV ; Epstein-Barr virus ; Epstein-Barr Virus Infections - complications ; Fatal Outcome ; Hematologic and hematopoietic diseases ; HIV ; HIV Infections - drug therapy ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma ; Lymphoma, AIDS-Related - diagnosis ; Lymphoma, AIDS-Related - drug therapy ; Lymphoma, AIDS-Related - etiology ; Male ; Medical sciences ; Middle Aged ; Mouth Neoplasms - diagnosis ; Mouth Neoplasms - drug therapy ; Mouth Neoplasms - etiology ; Neoplasms, Second Primary - diagnosis ; Neoplasms, Second Primary - drug therapy ; Neoplasms, Second Primary - etiology ; Oral ; Plasmablastic ; Sarcoma, Kaposi - diagnosis ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>Oral oncology, 2002, Vol.38 (1), p.96-102</ispartof><rights>2002 Elsevier Science Ltd</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-bd325d5b496e1f66430b9e689337f930493b3a3e0202ae2bfcc8b316e7fa13bc3</citedby><cites>FETCH-LOGICAL-c422t-bd325d5b496e1f66430b9e689337f930493b3a3e0202ae2bfcc8b316e7fa13bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S1368-8375(01)00018-5$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,4025,27925,27926,27927,45997</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13412920$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11755827$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Flaitz, C.M.</creatorcontrib><creatorcontrib>Nichols, C.M.</creatorcontrib><creatorcontrib>Walling, D.M.</creatorcontrib><creatorcontrib>Hicks, M.J.</creatorcontrib><title>Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations</title><title>Oral oncology</title><addtitle>Oral Oncol</addtitle><description>Plasmablastic lymphoma is a relatively new entity that is considered to be a diffuse large B-cell lymphoma with an unique immunophenotype and a predilection for the oral cavity. We present a 50 year-old HIV-positive, bisexual, white male with a CD4 count 300/mm 3 and a viral HIV-RNA polymerase chain reaction (PCR) load of 237 copies/ml, who developed a painful, purple-red mass in the edentulous area of the maxillary right first molar. Erythematous gingival enlargements of the interdental papillae were seen in three of the dental quadrants. In addition, the patient was being managed with antiretroviral therapy and liposomal doxorubicin for recurrent cutaneous Kaposi's sarcoma (KS). Although oral KS was suspected, the gingival lesions were biopsied because they were refractory to chemotherapy and a lymphoma could not be excluded. Histopathologic examination revealed a lymphoid malignant neoplasm, consistent with a plasmablastic lymphoma. Immunoreactivity with vs38c, CD79a, kappa light chain, and IgG was readily identified in tumor cells; while only focal cells expressed CD20 and LCA (CD45RB). CD56, CD3, lambda light chain, and EMA were non-reactive. EBV was detected in the tumor by Southern hybridization, PCR amplification, in situ hybridization for EBER-1 DNA, and immunohistochemistry for latent membrane protein-1. The same tumor was negative for HHV-8 by PCR. Recognition of plasmablastic lymphoma is important, because it represents an HIV-associated malignancy that predominately involves the oral cavity, may mimic KS and has a poor prognosis.</description><subject>AIDS</subject><subject>Antiretroviral Therapy, Highly Active - methods</subject><subject>Biological and medical sciences</subject><subject>CD38</subject><subject>Diagnosis, Differential</subject><subject>EBV</subject><subject>Epstein-Barr virus</subject><subject>Epstein-Barr Virus Infections - complications</subject><subject>Fatal Outcome</subject><subject>Hematologic and hematopoietic diseases</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma</subject><subject>Lymphoma, AIDS-Related - diagnosis</subject><subject>Lymphoma, AIDS-Related - drug therapy</subject><subject>Lymphoma, AIDS-Related - etiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mouth Neoplasms - diagnosis</subject><subject>Mouth Neoplasms - drug therapy</subject><subject>Mouth Neoplasms - etiology</subject><subject>Neoplasms, Second Primary - diagnosis</subject><subject>Neoplasms, Second Primary - drug therapy</subject><subject>Neoplasms, Second Primary - etiology</subject><subject>Oral</subject><subject>Plasmablastic</subject><subject>Sarcoma, Kaposi - diagnosis</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>1368-8375</issn><issn>1879-0593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtu1TAQQC0Eog_4BFA2oLIIeOzYidkgVEFbqVJBPLbW2JmoRnlcbF_Q_fu6vam67GZmFmdeh7FXwN8DB_3hB0jd1Z1s1QmHd5xz6Gr1hB1C15qaKyOflvoeOWBHKf0pkALFn7MDgFapTrSH7Pu3EdOErsQcfDXups31MuHHCufq_OJ3jSktPmCmvqI5h7yr_od8XW1imDDuqiXiWE04h4FSxhyWOb1gzwYcE71c8zH79fXLz9Pz-vLq7OL082XtGyFy7XopVK9cYzTBoHUjuTOkOyNlOxjJGyOdRElccIEk3OB95yRoagcE6bw8Zm_3czdx-bst6-0UkqdxxJmWbbItyEY3Sj8KQidMY4wpoNqDPi4pRRrs-qYFbm-l2zvp9tao5WDvpFtV-l6vC7Zuov6ha7VcgDcrgMnjOEScfUgPnGxAGMEL92nPUfH2L1C0yQeaPfUhks-2X8Ijp9wAokKeSA</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>Flaitz, C.M.</creator><creator>Nichols, C.M.</creator><creator>Walling, D.M.</creator><creator>Hicks, M.J.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>2002</creationdate><title>Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations</title><author>Flaitz, C.M. ; Nichols, C.M. ; Walling, D.M. ; Hicks, M.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-bd325d5b496e1f66430b9e689337f930493b3a3e0202ae2bfcc8b316e7fa13bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>AIDS</topic><topic>Antiretroviral Therapy, Highly Active - methods</topic><topic>Biological and medical sciences</topic><topic>CD38</topic><topic>Diagnosis, Differential</topic><topic>EBV</topic><topic>Epstein-Barr virus</topic><topic>Epstein-Barr Virus Infections - complications</topic><topic>Fatal Outcome</topic><topic>Hematologic and hematopoietic diseases</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma</topic><topic>Lymphoma, AIDS-Related - diagnosis</topic><topic>Lymphoma, AIDS-Related - drug therapy</topic><topic>Lymphoma, AIDS-Related - etiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mouth Neoplasms - diagnosis</topic><topic>Mouth Neoplasms - drug therapy</topic><topic>Mouth Neoplasms - etiology</topic><topic>Neoplasms, Second Primary - diagnosis</topic><topic>Neoplasms, Second Primary - drug therapy</topic><topic>Neoplasms, Second Primary - etiology</topic><topic>Oral</topic><topic>Plasmablastic</topic><topic>Sarcoma, Kaposi - diagnosis</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Flaitz, C.M.</creatorcontrib><creatorcontrib>Nichols, C.M.</creatorcontrib><creatorcontrib>Walling, D.M.</creatorcontrib><creatorcontrib>Hicks, M.J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Oral oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Flaitz, C.M.</au><au>Nichols, C.M.</au><au>Walling, D.M.</au><au>Hicks, M.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations</atitle><jtitle>Oral oncology</jtitle><addtitle>Oral Oncol</addtitle><date>2002</date><risdate>2002</risdate><volume>38</volume><issue>1</issue><spage>96</spage><epage>102</epage><pages>96-102</pages><issn>1368-8375</issn><eissn>1879-0593</eissn><abstract>Plasmablastic lymphoma is a relatively new entity that is considered to be a diffuse large B-cell lymphoma with an unique immunophenotype and a predilection for the oral cavity. We present a 50 year-old HIV-positive, bisexual, white male with a CD4 count 300/mm 3 and a viral HIV-RNA polymerase chain reaction (PCR) load of 237 copies/ml, who developed a painful, purple-red mass in the edentulous area of the maxillary right first molar. Erythematous gingival enlargements of the interdental papillae were seen in three of the dental quadrants. In addition, the patient was being managed with antiretroviral therapy and liposomal doxorubicin for recurrent cutaneous Kaposi's sarcoma (KS). Although oral KS was suspected, the gingival lesions were biopsied because they were refractory to chemotherapy and a lymphoma could not be excluded. Histopathologic examination revealed a lymphoid malignant neoplasm, consistent with a plasmablastic lymphoma. Immunoreactivity with vs38c, CD79a, kappa light chain, and IgG was readily identified in tumor cells; while only focal cells expressed CD20 and LCA (CD45RB). CD56, CD3, lambda light chain, and EMA were non-reactive. EBV was detected in the tumor by Southern hybridization, PCR amplification, in situ hybridization for EBER-1 DNA, and immunohistochemistry for latent membrane protein-1. The same tumor was negative for HHV-8 by PCR. Recognition of plasmablastic lymphoma is important, because it represents an HIV-associated malignancy that predominately involves the oral cavity, may mimic KS and has a poor prognosis.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>11755827</pmid><doi>10.1016/S1368-8375(01)00018-5</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1368-8375
ispartof Oral oncology, 2002, Vol.38 (1), p.96-102
issn 1368-8375
1879-0593
language eng
recordid cdi_proquest_miscellaneous_71346456
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects AIDS
Antiretroviral Therapy, Highly Active - methods
Biological and medical sciences
CD38
Diagnosis, Differential
EBV
Epstein-Barr virus
Epstein-Barr Virus Infections - complications
Fatal Outcome
Hematologic and hematopoietic diseases
HIV
HIV Infections - drug therapy
Human immunodeficiency virus
Human viral diseases
Humans
Infectious diseases
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma
Lymphoma, AIDS-Related - diagnosis
Lymphoma, AIDS-Related - drug therapy
Lymphoma, AIDS-Related - etiology
Male
Medical sciences
Middle Aged
Mouth Neoplasms - diagnosis
Mouth Neoplasms - drug therapy
Mouth Neoplasms - etiology
Neoplasms, Second Primary - diagnosis
Neoplasms, Second Primary - drug therapy
Neoplasms, Second Primary - etiology
Oral
Plasmablastic
Sarcoma, Kaposi - diagnosis
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
title Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T08%3A11%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasmablastic%20lymphoma:%20an%20HIV-associated%20entity%20with%20primary%20oral%20manifestations&rft.jtitle=Oral%20oncology&rft.au=Flaitz,%20C.M.&rft.date=2002&rft.volume=38&rft.issue=1&rft.spage=96&rft.epage=102&rft.pages=96-102&rft.issn=1368-8375&rft.eissn=1879-0593&rft_id=info:doi/10.1016/S1368-8375(01)00018-5&rft_dat=%3Cproquest_cross%3E71346456%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18294999&rft_id=info:pmid/11755827&rft_els_id=S1368837501000185&rfr_iscdi=true